Gavekal Capital Lowers stake in Becton Dickinson and Co (BDX)

Becton Dickinson and Co (BDX) : Gavekal Capital reduced its stake in Becton Dickinson and Co by 17.5% during the most recent quarter end. The investment management company now holds a total of 50,190 shares of Becton Dickinson and Co which is valued at $8,629,167 after selling 10,643 shares in Becton Dickinson and Co , the firm said in a disclosure report filed with the SEC on Oct 17, 2016.Becton Dickinson and Co makes up approximately 2.95% of Gavekal Capital’s portfolio.

Other Hedge Funds, Including , Gillespie Robinson Grimm Inc reduced its stake in BDX by selling 14,535 shares or 10.21% in the most recent quarter. The Hedge Fund company now holds 127,855 shares of BDX which is valued at $22,910,337. Becton Dickinson and Co makes up approx 3.54% of Gillespie Robinson Grimm Inc’s portfolio.Gofen Glossberg Il reduced its stake in BDX by selling 2 shares or 0.03% in the most recent quarter. The Hedge Fund company now holds 6,635 shares of BDX which is valued at $1,188,926. Becton Dickinson and Co makes up approx 0.05% of Gofen Glossberg Il’s portfolio.Central Bank Trust Co reduced its stake in BDX by selling 350 shares or 3.87% in the most recent quarter. The Hedge Fund company now holds 8,699 shares of BDX which is valued at $1,543,203. Becton Dickinson and Co makes up approx 0.44% of Central Bank Trust Co’s portfolio.Advisory Services Network boosted its stake in BDX in the latest quarter, The investment management firm added 236 additional shares and now holds a total of 5,803 shares of Becton Dickinson and Co which is valued at $1,029,452. Becton Dickinson and Co makes up approx 0.20% of Advisory Services Network’s portfolio.

Becton Dickinson and Co closed down -0.93 points or -0.54% at $171.93 with 8,66,534 shares getting traded on Friday. Post opening the session at $173.9, the shares hit an intraday low of $171.9 and an intraday high of $174.0499 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Becton Dickinson and Co reported $2.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.20. The company had revenue of $3198.00 million for the quarter, compared to analysts expectations of $3202.11 million. The company’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.05 EPS.

Many Wall Street Analysts have commented on Becton Dickinson and Co. Becton Dickinson and Co was Downgraded by Citigroup to ” Sell” on Sep 23, 2016.

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Becton Dickinson and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Becton Dickinson and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.